


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable diluent or carrier and an active ingredient of the general formula I:



wherein:

R_1 is optionally substituted hydrocarbyl or heterocyclyl;

R_2 is selected from the group consisting of H, (C_1-C_{12}) alkyl, (C_6-C_{14}) aryl- CH_2- , heteroaryl- CH_2- , alkylcarbonyl- CH_2- , (C_6-C_{14}) arylcarbonyl- CH_2- ~~or~~ and heteroarylcarbonyl- CH_2- ;

R_3 and R_4 each is selected from the group consisting of hydrogen, C_1-C_6 alkyl, (C_1-C_6) alkoxy (C_1-C_6) alkyl, and C_1-C_6 alkyl substituted by a group containing a basic nitrogen atom or by a 5-7 membered heterocyclic ring containing one or two

In re of: GREGOR8

heteroatoms, one of them being a basic nitrogen atom, or R₃ and R₄ together with the nitrogen atom to which they are attached form a 5-7 membered saturated heterocyclic ring containing one or two basic nitrogen atoms, optionally substituted on the additional nitrogen atom;

and pharmaceutically acceptable salts thereof.

Claims 2-17 (Canceled)

18. (Original) The pharmaceutical composition according to claim 1, wherein the compound of formula I is selected from the group consisting of:

2-[[(4-chlorophenyl)methyl]thio]-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide [Compound No. 1];

2-[[(4-methylphenyl)methyl]thio]-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide [Compound No. 2];

2-[[(3-fluorophenyl)methyl]thio]-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide [Compound No. 3];

In re of: GREGOR8

2-[(2-oxo-2-phenylethyl)thio]-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide [Compound No. 5]; and
2-[[2-[(3-chlorophenyl)methyl]thio]-3-pentyl-3,4-dihydro-4-oxo-N-(4-methylpiperazinyl)-7-quinazolinecarboxamide [Compound No. 4].

19. (Original) The pharmaceutical composition according to claim 1 wherein the compound of formula I is 2-[[[(6-nitro-4H-1,3-benzodioxin-8-yl)methyl]thio]-3-(2-propenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide (Compound No. 2010).

20. (Original) The pharmaceutical composition according to claim 1 wherein the compound of formula I is 2-[[[(5-acetyl-2-methoxyphenyl)methyl]thio]-3-(phenylmethyl)-3,4-dihydro-4-oxo-N-[3-(1H-imidazol-1-yl)propyl]-7-quinazolinecarboxamide (Compound No. 2011).

21. (Original) The pharmaceutical composition according to claim 1, wherein the compound of formula I is 2-

In re of: GREGOR8

[[(5-acetyl-2-methoxyphenyl)methyl]thio]-3-(phenylmethyl)-3,4-dihydro-4-oxo-N-(1-ethyl-piperidin-4-yl)-7-quinazoline-carboxamide (Compound No. 2012).

22. (Currently Amended) The pharmaceutical composition according to ~~any one of claims 1 to 21~~ claim 1, for the treatment or prevention of inflammatory or autoimmune diseases, disorders or conditions related to cell adhesion or cell migration mediated by heparan sulfate glycosaminoglycans (HS-GAGs).

Claims 23-28 (Canceled)

29. (Currently Amended) The pharmaceutical composition according to ~~any one of claims 1 to 21~~ claim 1, for modulating the anticoagulant activity of glycosaminoglycans.

30. (Original) The pharmaceutical composition according to claim 29, wherein the glycosaminoglycan is heparin.

31. (Currently Amended) The pharmaceutical composition according to ~~any one of claims 1 to 21~~ claim 1, capable of inhibiting the interaction of glycosaminoglycans with ~~L~~-selectins.

32. (Currently Amended) The pharmaceutical composition according to ~~any one of claims 1 to 21~~ claim 1, capable of inhibiting neutrophil infiltration in vivo.

Claims 33-42 (Canceled)

43. (Original) The compound 2-[[(6-nitro-4H-1,3-benzodioxin-8-yl)methyl]thio]-3-(2-propenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazoline carboxamide (Compound No. 2010).


44. (Original) The compound 2-[[(5-acetyl-2-methoxyphenyl) methyl]thio]-3-(phenyl-methyl)-3,4-dihydro-4-

In re of: GREGOR8

oxo-N-[3-(1H-imidazol-1-yl)propyl]-7-quinazoline-carboxamide
(Compound No. 2011).

45. (Original) The compound 2-[[(5-acetyl-2-methoxyphenyl) methyl]thio]-3-(phenyl-methyl)-3,4-dihydro-4-oxo-N-(1-ethyl-piperidin-4-yl)-7-quinazolinecarboxamide
(Compound No. 2012).

46. (Currently Amended) A method for the treatment or prevention of diseases, disorders or conditions related to cell adhesion or cell migration mediated by heparan sulfate glycosaminoglycans ~~(HS-GAGs)~~, comprising the step of administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a compound of the general formula I:



wherein:

R₁ is optionally substituted hydrocarbyl or heterocyclyl;

In re of: GREGOR8

R₂ is selected from the group consisting of H, (C₁-C₁₂)alkyl, (C₆-C₁₄)aryl-CH₂-, heteroaryl-CH₂-, alkylcarbonyl-CH₂-, (C₆-C₁₄)arylcarbonyl-CH₂-, ~~or~~ and heteroarylcarbonyl-CH₂-;

R₃ and R₄ each is selected from the group consisting of hydrogen, C₁-C₆ alkyl, (C₁-C₆)alkoxy(C₁-C₆)alkyl, and C₁-C₆ alkyl substituted by a group containing a basic nitrogen atom or by a 5-7 membered heterocyclic ring containing one or two heteroatoms, one of them being a basic nitrogen atom, or R₃ and R₄ together with the nitrogen atom to which they are attached form a 5-7 membered saturated heterocyclic ring containing one or two basic nitrogen atoms, optionally substituted on the additional nitrogen atom;

and pharmaceutically acceptable salts thereof.

Claims 47-62 (Canceled)

63. (Original) The method according to claim 46, wherein the compound of formula I is selected from the group consisting of:

2-[[(4-chlorophenyl)methyl]thio]-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide [Compound No. 1];

In re of: GREGOR8

2-[[(4-methylphenyl)methyl]thio]-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide [Compound No. 2];

2-[[(3-fluorophenyl)methyl]thio]-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide [Compound No. 3];

2-[(2-oxo-2-phenylethyl)thio]-3-(4-fluorophenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide [Compound No. 5]; and

2-[[2-[[(3-chlorophenyl)methyl]thio]-3-pentyl-3,4-dihydro-4-oxo-N-(4-methylpiperazinyl)-7-quinazolinecarboxamide [Compound No. 4].

64. (Original) The method according to claim 46, wherein the compound of formula I is 2-[[(6-nitro-4H-1,3-benzodioxin-8-yl)methyl]thio]-3-(2-propenyl)-3,4-dihydro-4-oxo-N-[3-(4-morpholinyl)propyl]-7-quinazolinecarboxamide (Compound No. 2010).

65. (Original) The method according to claim 46, wherein the compound of formula I is 2-[[(5-acetyl-2-methoxyphenyl)methyl]thio]-3-(phenylmethyl)-3,4-dihydro-4-oxo-

In re of: GREGOR8

N-[3-(1H-imidazol-1-yl)propyl]-7-quinazolinecarboxamide
(Compound No. 2011).

66. (Original) The method according to claim 46,
wherein the compound of formula I is 2-[[(5-acetyl-2-
methoxyphenyl)methyl]thio]-3-(phenylmethyl)-3,4-dihydro-4-oxo-
N-(1-ethyl-piperidin-4-yl)-7-quinazoline-carboxamide (Compound
No. 2012).

Claims 67-72 (Canceled)

73. (Original) A method for modulating the
anticoagulant activity of glycosaminoglycans which comprises
administering to a subject in need a therapeutically effective
amount of a compound of the general formula I in claim 46.

74. (Original) The method according to claim 73,
wherein the glycosaminoglycan is heparin.

75. (New) The pharmaceutical composition according to claim 1, wherein

R₁ is a hydrocarbyl selected from the group consisting of C₁-C₁₂ alkyl, C₂-C₁₂ alkenyl, C₂-C₁₂ alkynyl, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkenyl, C₆-C₁₄ aryl, (C₁-C₆)alkyl(C₆-C₁₄)aryl, and (C₆-C₁₄)aryl(C₁-C₁₂)alkyl, or such a hydrocarbyl substituted by at least one radical selected from the group consisting of C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₇-C₁₂ aralkyl, C₆-C₁₀ aryl, C₇-C₁₂ alkaryl, hydroxy, C₁-C₁₀ alkoxy, C₆-C₁₀ aryloxy, C₁-C₁₀ alkylthio, C₆-C₁₀ arylthio, C₆-C₁₀ arylamino, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkenyl, amino, C₁-C₁₀ alkylamino, di(C₁-C₁₀)-alkylamino, C₂-C₁₂ alkoxyalkyl, C₂-C₁₂ alkylthioalkyl, C₁-C₁₀ alkylsulfinyl, C₁-C₁₀ alkylsulfonyl, C₆-C₁₀ arylsulfonyl, hydroxy(C₁-C₁₀)alkyl, (C₆-C₁₀)aryloxy(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxycarbonyl, (C₆-C₁₀)aryloxycarbonyl, C₂-C₁₁ alkanoyl, (C₇-C₁₁)aroyl, fluoro(C₁-C₁₀)alkyl, oxo, nitro, nitro(C₁-C₁₀)alkyl, cyano, cyano(C₁-C₁₀)alkyl, aminocarbonyl, (C₁-C₁₀)alkylaminocarbonyl, di(C₁-C₁₀)-alkylaminocarbonyl, aminocarbonyl(C₁-C₁₀)alkyl, aminocarbonyl(C₆-C₁₀)aryl, aminosulfonyl, (C₁-C₁₀)alkylaminosulfonyl, di(C₁-C₁₀)-alkylaminosulfonyl, amidino, carboxy, sulfo, heterocyclyl, and -(CH₂)_m-Z-(C₁-C₁₀ alkyl), where m is 1 to 8 and Z is oxygen or sulfur; or R₁ is a heterocyclyl radical derived from a mono-

or poly-cyclic ring containing one to three heteroatoms selected from the group consisting of N, O and S;

R₂ is selected from the group consisting of (C₆-C₁₄)aryl-CH₂-, (C₆-C₁₄)arylcarbonyl-CH₂-, heteroaryl-CH₂- and heteroarylcarbonyl-CH₂-, wherein said aryl or heteroaryl is unsubstituted or substituted by at least one radical selected from the group consisting of C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₇-C₁₂ aralkyl, C₆-C₁₀ aryl, C₇-C₁₂ alkaryl, hydroxy, C₁-C₁₀ alkoxy, C₆-C₁₀ aryloxy, C₁-C₁₀ alkylthio, C₆-C₁₀ arylthio, C₆-C₁₀ arylamino, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkenyl, amino, C₁-C₁₀ alkylamino, di(C₁-C₁₀)-alkylamino, C₂-C₁₂ alkoxyalkyl, C₂-C₁₂ alkylthioalkyl, C₁-C₁₀ alkylsulfinyl, C₁-C₁₀ alkylsulfonyl, C₆-C₁₀ arylsulfonyl, hydroxy(C₁-C₁₀)alkyl, (C₆-C₁₀)aryloxy(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxycarbonyl, (C₆-C₁₀)aryloxycarbonyl, C₂-C₁₁ alkanoyl, (C₇-C₁₁)aroyl, fluoro(C₁-C₁₀)alkyl, oxo, nitro, nitro(C₁-C₁₀)alkyl, cyano, cyano(C₁-C₁₀)alkyl, aminocarbonyl, (C₁-C₁₀)alkylaminocarbonyl, di(C₁-C₁₀)-alkylaminocarbonyl, aminocarbonyl(C₁-C₁₀)alkyl, aminocarbonyl(C₆-C₁₀)aryl, aminosulfonyl, (C₁-C₁₀)alkylaminosulfonyl, di(C₁-C₁₀)-alkylaminosulfonyl, amidino, carboxy, sulfo, heterocyclyl, and -(CH₂)_m-Z-(C₁-C₁₀ alkyl), where m is 1 to 8 and Z is oxygen or sulfur; and wherein said heteroaryl is selected from the group consisting of pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl thiazolyl, isothiazolyl,

pyridyl, 1,3-benzodioxanyl, pyrazinyl, pyrimidinyl, 1,3,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, thiazinyl, quinolinyl, isoquinolinyl, benzofuryl, isobenzofuryl, indolyl, imidazo[1,2-a]pyridyl, pyrido[1,2-a]pyrimidinyl, benzimidazolyl, benzthiazolyl, and benzoxazolyl;

R_3 is hydrogen; and

R_4 is selected from the groups consisting of:

(i) (C_1-C_6) alkoxy (C_1-C_6) alkyl;

(ii) (C_1-C_6) alkyl substituted by a group selected from the group consisting of an amino group $-NR_5R_6$, an ammonium group $-N^+(R_5R_6R_7)$, a hydrazine group $-NR_5-NR_6R_7$, a hydrazone group $-NR_5-N^+(R_6R_7R_8)$, an ammoniumoxy group $-O-N^+(R_5R_6)$, an imine group $-C=NR_5R_6$, an iminium group $-C=N^+(R_5R_6R_7)$, a guanidine group $-NR_5-C(=NH)-NR_6R_7$, and a guanidinium group $-NR_5-C(=NH)-N^+(R_6R_7R_8)$, wherein each of R_5 , R_6 , R_7 and R_8 is H, or optionally substituted C_1-C_{10} alkyl or C_6-C_{10} aryl; and

(iii) (C_1-C_6) alkyl substituted by a 5-7 membered heterocyclic ring selected from the group consisting of pyrrolidine, pyrroline, pyrrol, imidazolidine, imidazoline, imidazole, piperidine, dihydropyridine, tetrahydropyridine, pyridine, 1,2-pyrazine, tetrahydropyrimidine, dihydropyrimidine, pyrimidine, 1,4-pyrazine, 1,4-tetrahydropyrazine, 1,4-dihydropyrazine, piperazine, diazepine, oxazolidine, oxazoline, oxazole, morpholino, 1,4-

In re of: GREGOR8

dihydrooxazine, 1,4-oxazine. thiazolidine, thiazoline, thiaazole, thiomorpholino, 1,4-dihydrothiazine, and 1,4-thiazine; or

R₃ and R₄ together with the nitrogen atom to which they are attached form a 5-7 membered saturated heterocyclic ring containing one or two basic nitrogen atoms selected from the group consisting of pyrrolidine, imidazolidine, piperidine, piperazine, and piperazine substituted at the additional nitrogen atom by C₁-C₆ alkyl or by C₁-C₆ alkyl substituted by halo, hydroxy, C₁-C₆ alkoxy or C₆-C₁₀ aryl, or C₂-C₇ alkoxycarbonyl.

76. (New) The pharmaceutical composition according to claim 75, wherein R₁ is selected from the group consisting of pentyl, allyl, phenyl, 4-fluorophenyl, benzyl, 2-furylmethyl and (tetrahydro-2-furyl)methyl;

R₂ is selected from the group consisting of phenyl-CH₂-, 4-methylphenyl-CH₂-, 3-fluorophenyl-CH₂-, 4-fluorophenyl-CH₂-, 3-chlorophenyl-CH₂-, 4-chlorophenyl-CH₂-, phenylcarbonyl-CH₂-, 4-fluoro-phenylcarbonyl-CH₂-, 4-chloro-phenylcarbonyl-CH₂-, 4-pyridyl-CH₂- and 4-oxo-4H-pyrido[1,2-a]pyrimidin-yl-CH₂-;

R₃ is hydrogen; and

R₄ is selected from the group consisting of 2-

In re of: GREGOR8

methoxyethyl, 3-(4-morpholinyl)propyl and 3-(1-piperidinyl)propyl; or

R₃ and R₄ together with the nitrogen atom to which they are attached form 4-methylpiperazinyl or 1-piperazinyl-4-carboxylic acid ethyl ester.

77. (New) The pharmaceutical composition according to claim 22, wherein said inflammatory or autoimmune disease, disorder or condition is selected from the group consisting of sepsis, wound associated sepsis, post-septic shock, ischemic leukocyte-mediated tissue damage (ischemia-reperfusion injury) such as myocardial ischemia, platelet-mediated pathologies such as atherosclerosis and clotting, cardiomyopathic disease, stroke, restenosis, infectious meningitis, encephalitis, allergic conjunctivitis, organ/tissue transplant rejection (such as skin, kidney, heart, lung, liver, bone marrow, cornea, pancreas, small bowel, autologous bone marrow transplantation), "graft versus host" disease (GVHD), lupus, frost-bite injury or shock, acute leukocyte-mediated lung injury (such as adult respiratory distress syndrome), asthma, allergic rhinitis, acute pancreatitis, traumatic shock, traumatic brain injury, acute and chronic inflammation such as atopic dermatitis, psoriasis, contact dermal hypersensitivity

and inflammatory bowel disease such as Crohn's disease and ulcerative colitis, rheumatoid arthritis, retinitis; multiple sclerosis; amyloid disorders such as Alzheimer's disease and type II diabetes; angiogenesis pathologies selected from the group consisting of tumor angiogenesis, ophthalmologic disorders such as neovascular glaucoma, diabetic retinopathy, macular degeneration (particularly age-related macular degeneration) and uveitis, reperfusion of gastric ulcer, contraception and inducing abortion at early stages of pregnancy; viral disorders selected from the group consisting of hepatitis C, hepatitis B, influenza, rhinovirus infections, cytomegalovirus infections, AIDS and respiratory syncytial virus infections; bone degradation, osteoporosis, osteoarthritis, kidney disease including glomerulonephritis and nephritis; and bacterial infections.

78. (New) The pharmaceutical composition according to claim 22, wherein said disease is cancer or tumor metastasis.

79. (New) The pharmaceutical composition according to claim 31, wherein said selectin is L-selectin.

80. (New) The method according to claim 46, wherein R_1 is hydrocarbyl selected from the group consisting of C_1 - C_{12} alkyl, C_2 - C_{12} alkenyl, C_2 - C_{12} alkynyl, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkenyl, C_6 - C_{14} aryl, $(C_1$ - $C_6)$ alkyl(C_6 - C_{14})aryl, and $(C_6$ - C_{14})aryl(C_1 - C_{12})alkyl, or such a hydrocarbyl substituted by at least one radical selected from the group consisting of C_1 - C_{10} alkyl, C_2 - C_{10} alkenyl, C_2 - C_{10} alkynyl, C_7 - C_{12} aralkyl, C_6 - C_{10} aryl, C_7 - C_{12} alkaryl, hydroxy, C_1 - C_{10} alkoxy, C_6 - C_{10} aryloxy, C_1 - C_{10} alkylthio, C_6 - C_{10} arylthio, C_6 - C_{10} arylamino, C_3 - C_{10} cycloalkyl, C_3 - C_{10} cycloalkenyl, amino, C_1 - C_{10} alkylamino, di(C_1 - C_{10})-alkylamino, C_2 - C_{12} alkoxyalkyl, C_2 - C_{12} alkylthioalkyl, C_1 - C_{10} alkylsulfinyl, C_1 - C_{10} alkylsulfonyl, C_6 - C_{10} arylsulfonyl, hydroxy(C_1 - C_{10})alkyl, $(C_6$ - $C_{10})$ aryloxy(C_1 - C_{10})alkyl, $(C_1$ - $C_{10})$ alkoxycarbonyl, $(C_6$ - $C_{10})$ aryloxycarbonyl, C_2 - C_{11} alkanoyl, $(C_7$ - $C_{11})$ aroyle, fluoro(C_1 - C_{10})alkyl, oxo, nitro, nitro(C_1 - C_{10})alkyl, cyano, cyano(C_1 - C_{10})alkyl, aminocarbonyl, $(C_1$ - $C_{10})$ alkylaminocarbonyl, di(C_1 - C_{10})-alkylaminocarbonyl, aminocarbonyl(C_1 - C_{10})alkyl, aminocarbonyl(C_6 - C_{10})aryl, aminosulfonyl, $(C_1$ - $C_{10})$ alkylaminosulfonyl, di(C_1 - C_{10})-alkylaminosulfonyl, amidino, carboxy, sulfo, heterocyclyl, and $-(CH_2)_m-Z-(C_1$ - C_{10} alkyl), where m is 1 to 8 and Z is oxygen or sulfur; or R_1 is a heterocyclyl radical derived from a mono-

In re of: GREGOR8

or poly-cyclic ring containing one to three heteroatoms selected from the group consisting of N, O and S;

R₂ is selected from the group consisting of (C₆-C₁₄)aryl-CH₂-, (C₆-C₁₄)arylcarbonyl-CH₂-, heteroaryl-CH₂- and heteroarylcarbonyl-CH₂-, wherein said aryl or heteroaryl is unsubstituted or substituted by at least one radical selected from the group consisting of C₁-C₁₀ alkyl, C₂-C₁₀ alkenyl, C₂-C₁₀ alkynyl, C₇-C₁₂ aralkyl, C₆-C₁₀ aryl, C₇-C₁₂ alkaryl, hydroxy, C₁-C₁₀ alkoxy, C₆-C₁₀ aryloxy, C₁-C₁₀ alkylthio, C₆-C₁₀ arylthio, C₆-C₁₀ arylamino, C₃-C₁₀ cycloalkyl, C₃-C₁₀ cycloalkenyl, amino, C₁-C₁₀ alkylamino, di(C₁-C₁₀)-alkylamino, C₂-C₁₂ alkoxyalkyl, C₂-C₁₂ alkylthioalkyl, C₁-C₁₀ alkylsulfinyl, C₁-C₁₀ alkylsulfonyl, C₆-C₁₀ arylsulfonyl, hydroxy(C₁-C₁₀)alkyl, (C₆-C₁₀)aryloxy(C₁-C₁₀)alkyl, (C₁-C₁₀)alkoxycarbonyl, (C₆-C₁₀)aryloxycarbonyl, C₂-C₁₁ alkanoyl, (C₇-C₁₁)aroyl, fluoro(C₁-C₁₀)alkyl, oxo, nitro, nitro(C₁-C₁₀)alkyl, cyano, cyano(C₁-C₁₀)alkyl, aminocarbonyl, (C₁-C₁₀)alkylaminocarbonyl, di(C₁-C₁₀)-alkylaminocarbonyl, aminocarbonyl(C₁-C₁₀)alkyl, aminocarbonyl(C₆-C₁₀)aryl, aminosulfonyl, (C₁-C₁₀)alkylaminosulfonyl, di(C₁-C₁₀)-alkylaminosulfonyl, amidino, carboxy, sulfo, heterocyclyl, and -(CH₂)_m-Z-(C₁-C₁₀ alkyl), where m is 1 to 8 and Z is oxygen or sulfur; and wherein said heteroaryl is selected from the group consisting of pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl thiazolyl, isothiazolyl,

pyridyl, 1,3-benzodioxanyl, pyrazinyl, pyrimidinyl, 1,3,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, thiazinyl, quinolinyl, isoquinolinyl, benzofuryl, isobenzofuryl, indolyl, imidazo[1,2-a]pyridyl, pyrido[1,2-a]pyrimidinyl, benzimidazolyl, benzthiazolyl, and benzoxazolyl;

R_3 is hydrogen; and

R_4 is selected from the groups consisting of:

(i) (C_1-C_6) alkoxy (C_1-C_6) alkyl;

(ii) (C_1-C_6) alkyl substituted by a group selected from the group consisting of an amino group $-NR_5R_6$, an ammonium group $-N^+(R_5R_6R_7)$, a hydrazine group $-NR_5-NR_6R_7$, a hydrazone group $-NR_5-N^+(R_6R_7R_8)$, an ammoniumoxy group $-O-N^+(R_5R_6)$, an imine group $-C=NR_5R_6$, an iminium group $-C=N^+(R_5R_6R_7)$, a guanidine group $-NR_5-C(=NH)-NR_6R_7$, and a guanidinium group $-NR_5-C(=NH)-N^+(R_6R_7R_8)$, wherein each of R_5 , R_6 , R_7 and R_8 is H, or optionally substituted C_1-C_{10} alkyl or C_6-C_{10} aryl; and

(iii) (C_1-C_6) alkyl substituted by a 5-7 membered heterocyclic ring selected from the group consisting of pyrrolidine, pyrroline, pyrrol, imidazolidine, imidazoline, imidazole, piperidine, dihydropyridine, tetrahydropyridine, pyridine, 1,2-pyrazine, tetrahydropyrimidine, dihydropyrimidine, pyrimidine, 1,4-pyrazine, 1,4-tetrahydropyrazine, 1,4-dihydropyrazine, piperazine, diazepine, oxazolidine, oxazoline, oxazole, morpholino, 1,4-

In re of: GREGOR8

dihydrooxazine, 1,4-oxazine. thiazolidine, thiazoline, thiaazole, thiomorpholino, 1,4-dihydrothiazine, and 1,4-thiazine; or

R₃ and R₄ together with the nitrogen atom to which they are attached form a 5-7 membered saturated heterocyclic ring containing one or two basic nitrogen atoms selected from the group consisting of pyrrolidine, imidazolidine, piperidine, piperazine, and piperazine substituted at the additional nitrogen atom by C₁-C₆ alkyl or by C₁-C₆ alkyl substituted by halo, hydroxy, C₁-C₆ alkoxy or C₆-C₁₀ aryl, or C₂-C₇ alkoxycarbonyl.

81. (New) The method according to claim 80, wherein R₁ is selected from the group consisting of pentyl, allyl, phenyl, 4-fluorophenyl, benzyl, 2-furylmethyl and (tetrahydro-2-furyl)methyl;

R₂ is selected from the group consisting of phenyl-CH₂-, 4-methylphenyl-CH₂-, 3-fluorophenyl-CH₂-, 4-fluorophenyl-CH₂-, 3-chlorophenyl-CH₂-, 4-chlorophenyl-CH₂-, phenylcarbonyl-CH₂-, 4-fluoro-phenylcarbonyl-CH₂-, 4-chloro-phenylcarbonyl-CH₂-, 4-pyridyl-CH₂- and 4-oxo-4H-pyrido[1,2-a]pyrimidin-yl-CH₂-;

R₃ is hydrogen; and

R₄ is selected from the group consisting of 2-

In re of: GREGOR8

methoxyethyl, 3-(4-morpholinyl)propyl and 3-(1-piperidinyl)propyl; or

R₃ and R₄ together with the nitrogen atom to which they are attached form 4-methylpiperazinyl or 1-piperazinyl-4-carboxylic acid ethyl ester.

82. (New) The method according to claim 46, for the treatment or prevention of inflammatory or autoimmune diseases, disorders or conditions related to cell adhesion or cell migration mediated by heparan sulfate glycosaminoglycans.

83. (New) The method according to claim 82, wherein said inflammatory or autoimmune disease, disorder or condition is selected from the group consisting of sepsis, wound associated sepsis, post-septic shock, ischemic leukocyte-mediated tissue damage (ischemia-reperfusion injury) such as myocardial ischemia, platelet-mediated pathologies such as atherosclerosis and clotting, cardiomyopathic disease, stroke, restenosis, infectious meningitis, encephalitis, allergic conjunctivitis, organ/tissue transplant rejection (such as skin, kidney, heart, lung, liver, bone marrow, cornea, pancreas, small bowel, autologous bone marrow transplantation), "graft versus host" disease (GVHD), lupus,

In re of: GREGOR8

frost-bite injury or shock, acute leukocyte-mediated lung injury (such as adult respiratory distress syndrome), asthma, allergic rhinitis, acute pancreatitis, traumatic shock, traumatic brain injury, acute and chronic inflammation such as atopic dermatitis, psoriasis, contact dermal hypersensitivity and inflammatory bowel disease such as Crohn's disease and ulcerative colitis, rheumatoid arthritis, retinitis; multiple sclerosis; amyloid disorders such as Alzheimer's disease and type II diabetes; angiogenesis pathologies selected from the group consisting of tumor angiogenesis, ophthalmologic disorders such as neovascular glaucoma, diabetic retinopathy, macular degeneration (particularly age-related macular degeneration) and uveitis, reperfusion of gastric ulcer, contraception and inducing abortion at early stages of pregnancy; viral disorders selected from the group consisting of hepatitis C, hepatitis B, influenza, rhinovirus infections, cytomegalovirus infections, AIDS and respiratory syncytial virus infections; bone degradation, osteoporosis, osteoarthritis, kidney disease including glomerulonephritis and nephritis; and bacterial infections.

84. (New) The method according to claim 82, wherein said disease is cancer or tumor metastasis.